{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:42:06Z","timestamp":1772120526957,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013017","name":"Vanderbilt University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.celrep.2022.111807","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T11:23:19Z","timestamp":1670930599000},"page":"111807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines"],"prefix":"10.1016","volume":"41","author":[{"given":"Nagarajan","family":"Raju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subash","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lovkesh","family":"Karwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansi J.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Carnahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivelin S.","family":"Georgiev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2022.111807_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.vaccine.2016.10.070","article-title":"Dengue vaccine: WHO position paper, July 2016 - recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.111807_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2022.111807_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tim.2013.12.011","article-title":"Global spread of dengue virus types: mapping the 70 year history","volume":"22","author":"Messina","year":"2014","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.celrep.2022.111807_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0022-2014","article-title":"Dengue antibody-dependent enhancement: knowns and unknowns","volume":"2","author":"Halstead","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.celrep.2022.111807_bib5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.celrep.2022.111807_bib6","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2010.01.022","article-title":"Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys","volume":"28","author":"Clements","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.111807_bib7","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2022.111807_bib8","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2022.111807_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.111807_bib10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.111807_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40259-022-00531-z","article-title":"Dengue vaccines: an update","volume":"36","author":"Torres-Flores","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.celrep.2022.111807_bib12","doi-asserted-by":"crossref","first-page":"e0005179","DOI":"10.1371\/journal.pntd.0005179","article-title":"The Impact of the newly licensed dengue vaccine in endemic countries","volume":"10","author":"Aguiar","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.celrep.2022.111807_bib13","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.3390\/molecules26226768","article-title":"Updates on dengue vaccine and antiviral: where are we heading?","volume":"26","author":"Norshidah","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.celrep.2022.111807_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7006a1","article-title":"Dengue vaccine: recommendations of the advisory committee on immunization practices, United States, 2021","volume":"70","author":"Paz-Bailey","year":"2021","journal-title":"MMWR. Recomm. Rep."},{"key":"10.1016\/j.celrep.2022.111807_bib15","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.111807_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.celrep.2022.111807_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/infdis\/jiaa346","article-title":"Characterization of the type-specific and cross-reactive B-cell responses elicited by a live-attenuated tetravalent dengue vaccine","volume":"223","author":"Michlmayr","year":"2021","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2022.111807_bib18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/infdis\/jiy063","article-title":"Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate","volume":"217","author":"Swanstrom","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.celrep.2022.111807_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.1233989","article-title":"Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization","volume":"340","author":"Georgiev","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.celrep.2022.111807_bib20","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1093\/bioinformatics\/btz097","article-title":"NFPws: a web server for delineating broadly neutralizing antibody specificities from serum HIV-1 neutralization data","volume":"35","author":"Raju","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2022.111807_bib21","doi-asserted-by":"crossref","first-page":"e1006148","DOI":"10.1371\/journal.ppat.1006148","article-title":"Mapping polyclonal HIV-1 antibody responses via next-generation neutralization fingerprinting","volume":"13","author":"Doria-Rose","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2022.111807_bib22","doi-asserted-by":"crossref","first-page":"e1006934","DOI":"10.1371\/journal.ppat.1006934","article-title":"Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes","volume":"14","author":"Gallichotte","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2022.111807_bib23","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3390\/v13101957","article-title":"Neutralization of dengue virus serotypes by sera from dengue-infected individuals is preferentially directed to heterologous serotypes and not against the autologous serotype present in acute infection","volume":"13","author":"Auerswald","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2022.111807_bib24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2022.111807_bib25","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00705-008-0249-9","article-title":"Detection of concurrent infection with multiple dengue virus serotypes in Thai children by ELISA and nested RT-PCR assay","volume":"153","author":"Chinnawirotpisan","year":"2008","journal-title":"Arch. Virol."},{"key":"10.1016\/j.celrep.2022.111807_bib26","first-page":"375","article-title":"Description of high rates of unapparent and simultaneous multiple dengue virus infection in a Colombian jungle settlement","volume":"33","author":"Castellanos","year":"2016","journal-title":"Trop. Biomed."},{"key":"10.1016\/j.celrep.2022.111807_bib29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.celrep.2022.111807_bib30","doi-asserted-by":"crossref","first-page":"12233","DOI":"10.1128\/JVI.00247-14","article-title":"Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones","volume":"88","author":"Smith","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2022.111807_bib31","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2022.111807_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika-dengue virus antibody cross-neutralization","volume":"536","author":"Barba-Spaeth","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2022.111807_bib33","doi-asserted-by":"crossref","first-page":"e00873","DOI":"10.1128\/mBio.00873-13","article-title":"The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein","volume":"4","author":"Smith","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.celrep.2022.111807_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11262-011-0602-z","article-title":"Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus","volume":"43","author":"Kelly","year":"2011","journal-title":"Virus Gene."},{"key":"10.1016\/j.celrep.2022.111807_bib35","doi-asserted-by":"crossref","first-page":"e1000821","DOI":"10.1371\/journal.ppat.1000821","article-title":"Natural strain variation and antibody neutralization of dengue serotype 3 viruses","volume":"6","author":"Wahala","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2022.111807_bib36","doi-asserted-by":"crossref","first-page":"e3230","DOI":"10.1371\/journal.pntd.0003230","article-title":"Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies","volume":"8","author":"Buddhari","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.celrep.2022.111807_bib37","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.1128\/JVI.01314-13","article-title":"Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection","volume":"87","author":"Sukupolvi-Petty","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2022.111807_bib27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2022.111807_bib28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect. Dis."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124722016953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124722016953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:58:15Z","timestamp":1761911895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124722016953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2211124722016953"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2022.111807","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.02.467518","asserted-by":"object"}]},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2022.111807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"111807"}}